Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of cystic fibrosis (sweat test/genotype)~2. Aged 8 years or older~3. Have FEV1 between 40% and 80% of predicted for height, age and gender OR a decrease in FEV1 of 20% or more than that recorded 6-12 months previously.~4. As determined by the investigator, are capable and willing to~   * Use the study diary as required for this protocol~  * Able to perform all of the techniques necessary to measure lung function~  * Able to administer the dry powder mannitol~5. Are capable of and have given informed consent~6. Clinically stable at study entry~Exclusion Criteria:~1. Investigators, site personnel directly affiliated with this study, and their immediate families.~2. Subjects under the age of 8 years.~3. Subjects with currently active asthma~4. Subjects using hypertonic saline treatment in the last 2 weeks~5. Considered terminally ill or listed for transplantation~6. Requiring home oxygen or assisted ventilation~7. Colonisation with Burkholderia cepacia~8. Significant episode of hemoptysis (\>60 mls) in the previous 12 months~9. Myocardial Infarction in the six months prior to enrolment.~10. Cerebral Vascular Accident in the six months prior to enrolment.~11. Ocular surgery in the three months prior to enrolment.~12. Abdominal surgery in the three months prior to enrolment.~13. Subjects who are breast feeding or pregnant.~14. Female subjects of reproductive capability, not using a reliable form of contraception~15. Inability to obtain informed consent from the subject or subject's authorised representative.~16. Subjects who have participated in another investigative drug study parallel to, or within 4 weeks of study entry.~17. Known intolerance to mannitol or beta2 agonists.~18. Uncontrolled hypertension - systolic BP \> 160 and or diastoli

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).